Surgery today
Survival outcomes of alectinib in postoperative recurrent ALK-rearranged lung cancer.
Ryo Miyata, Masatsugu Hamaji, Hiroyuki Kurakami, Ryo Nakanobo, Masashi Kobayashi, Ryota Sumitomo, Masaka Ikeda, Masashi Ishikawa, Takehisa Fukada, Hiroaki Sakai, Hiromi Oda, Akihiro Ohsumi, Tetsuji Moriya, Hiroya Yamagishi, Hiroshi Date
Published: 202510.1007/s00595-025-03196-7
Abstract
The clinical benefits of anaplastic lymphoma kinase (ALK) inhibitors in patients with recurrent ALK-rearranged lung adenocarcinoma after surgical resection remain poorly understood. We retrospectively reviewed the medical records of 10 patients who r…
Preview only. Read the full abstract at the source